There is a lot to expect and watch out in the cancer research community. Cancer institutions have been on the rise to produce better ways of managing cancer. We could be possibly expecting a cure in the near future. One institution that has been working hard to better treat cancer is Seattle Genetics. It is a firm medicine company that has broadened the application of its drugs. The organization recently announced its plan to expand their current drug pipeline with new medications.
The move has seen Seattle Genetics rise to become an institute of cancer research. Adcetris is the main drug produced by the company. The drug is mostly applicable in cancer treatment applications. Information received from its CEO, Clay Siegall indicates that the drug has been experimented on up 70 different cases on lymphomas. Under its CEO, the drug company plans to hire more employees and produce more drugs. The hiring is an ambitious plan and is going to be the biggest hiring the company has had. The company today has more than 800 employees. The company has grown to have approximately 20 offices in Switzerland and plans to expand more.
About Clay Siegall
Dr. Siegall has played a huge role in steering Seattle Genetics on its path to success. He has managed to secure a large amount of financing for the company. He has been behind the company’s initial major funding that took place in 2001. Since then, he has gone to secure other funding from private sources that amount to more than $675 million.
Siegall has made a significant impact under his company in the Cancer research platform. His promise of unleashing 12 new cancer drugs has given hope to people who suffer from Cancer. Dr. Siegall’s educational background explains his excellence in his work. He graduated from George Washington University with a Ph.D. in Genetics. He has a Bachelor of Science in Zoology with a degree from Maryland University. Before becoming CEO of Seattle Genetics, he worked for several research organizations. He has also worked with the National Institutes of Health and Cancer. He today is the founder and CEO of Seattle Genetics where he has led the company to paths of great success.
In January of 2013, the biotechnology-based company Mirna Therapeutics announced that Seattle Genetics co-founder, Chairman of the Board of Directors, and current Chief Executive Officer Clay Siegall, Ph.D. would be appointed as a member of the Board of Directors as an outside director.
Mirna Therapeutics is an Austin, Texas-based company founded in 2007 that is focused on microRNA in therapeutics. The company’s focus is currently in cancer research, which Dr. Siegall has a background in. The President and CEO of Mira, Dr. Paul Lammers, said that they are excited to someone with the experience that Dr. Siegall has joining their Board of Directors. He expects Dr. Siegall to help guide them towards advancements in developing their microRNA-based therapeutics.
Clay Siegall, Ph.D. co-founded Seattle Genetics in 1998 and is the company’s current President, Chief Executive Officer, and Chairman for the Board of Directors. With Dr. Siegall‘s direction, the Seattle Genetics has successfully created antibody-based therapies for cancer patients whose medical needs were not being met. In addition to being a part of Seattle Genetics, Dr. Siegall is a published author with over 70 works published. He also holds 15 patents.
Before starting Seattle Genetics, Clay Siegall attended the University of Maryland where he received his Bachelor in Science in Zoology. He then attended George Washington University where he received his PhD in Genetics. After graduating he worked for the National Cancer Institute, National Institutes of Health as well as the Bristol-Myers
Squibb Pharmaceutical Research Institute before co-founding Seattle Genetics.
Seattle Genetic is a leading biotechnology company that develops clinical and preclinical products. The company was founded in 1998 and over the years, it has developed and commercialized innovative antibody-drug conjugate (ADC) for cancer treatment. It is built on a foundation of rigorous research, scientific innovation and drug development practices.
ADC technology reduces toxic effects of chemotherapy and enhances antitumor activity. There are several ADC programs is SGN-CD33A is used in acute myeloid leukaemia, and SGN-CD19A is used in non-Hodgkin lymphoma. ADCETRIS therapy has been used to treat over 15,000 lymphoma patients, and the product is available in 65 countries. It has also been approved by US Food and Drug Administration. The sugar-engineered antibody (SEA) technology increases the potency of monoclonal antibodies and is complementary to ADC technology. SEA-CD40 will be used for solid tumors and is the first antibody to be developed using the SEA technology.
The company has its headquarters in Bothell Washington and is traded on Nasdaq Stock Market. It has partnered with Genentech, Bayer Pharmaceuticals Corporation, Curagen and Medimmune. It also has licenses with biotechnology and pharmaceutical companies such as Celldex Therapeutics Inc., GlaxoSmithKline LLC, AbbVie Biotechnology Ltd, Pfizer, Oxford Bio Therapeutics Inc. and Genentech (Roche). Collaboration with Unnum Therapeutics has generated $645 Million in the development of anti-body T-cell receptors (ACTR) cancer therapies.
Clay Siegall is passionate about addressing the unmet medical needs in the field of oncology, and thus he is the co-founder, president and CEO of Seattle Genetics. He has a PhD in Genetics from The George Washington and Bachelors in Zoology from the University of Maryland. Clay is an author with over 70 publications and is a holder of 15 patents. Before founding Seattle, he worked at Bristol-Myers Squibb Pharmaceutical Research Institute, National Institute of Health and National Cancer Institute.
He is board chairperson and CEO of Seattle Genetics and a board member of Alder Pharmaceuticals Inc, Washington Biotech and BioMedical Association (WBBA), Fred Hutchinson Cancer Research Centre and Mirna Therapeutics Inc. Clay has several awards such as Alumnus of the Year for Computer, Math and Natural Sciences from the University of Maryland in 2013 and Entrepreneur of the Year from Pacific Northwest from Ernest and Young in 2012.